Overview

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

Status:
Completed

Trial end date:
2019-10-04

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate whether administration of bimekizumab has an effect on the expected production of antibody titers to the influenza vaccine.

Phase:

Phase 1

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Treatments:

Antibodies